Applicability of ENCHANTED trial results to current acute ischemic stroke patients eligible for intravenous thrombolysis in England and Wales: Comparison with the Sentinel Stroke National Audit Programme registry

dc.contributor.authorRobinson, Thompson
dc.contributor.authorBray, Benjamin
dc.contributor.authorPaley, Lizz
dc.contributor.authorSprigg, Nikola
dc.contributor.authorWan, Xia
dc.contributor.authorArima, Hisatomi
dc.contributor.authorBath, Philip
dc.contributor.authorBroderick, Joseph
dc.contributor.authorDurham, Alice
dc.contributor.authorKim, Jong
dc.contributor.authorLavados, Pablo
dc.contributor.authorLee, Tsong-Hai
dc.contributor.authorMartins, Sheila
dc.contributor.authorNguyen, Thang
dc.contributor.authorPandian, Jeyaraj
dc.contributor.authorParsons, Mark
dc.contributor.authorPontes-Neto, Octavio
dc.contributor.authorRicci, Stefano
dc.contributor.authorSharma, Vijay
dc.contributor.authorWang, Jiguang
dc.contributor.authorWoodward, Mark
dc.contributor.authorRudd, Anthony
dc.contributor.authorChalmers, John
dc.contributor.authorAnderson, Craig
dc.contributor.authorENCHANTED Investigators
dc.date.accessioned2020-09-04T16:32:35Z
dc.date.available2020-09-04T16:32:35Z
dc.date.issued2019-10
dc.description.abstractBackground: Randomized controlled trials provide high-level evidence, but the necessity to include selected patients may limit the generalisability of their results. Methods: Comparisons were made of baseline and outcome data between patients with acute ischemic stroke (AIS) recruited into the alteplase-dose arm of the international, multi-center, Enhanced Control of Hypertension and Thrombolysis Stroke study (ENCHANTED) in the United Kingdom (UK), and alteplase-treated AIS patients registered in the UK Sentinel Stroke National Audit Programme (SSNAP) registry, over the study period June 2012 to October 2015. Results: There were 770 AIS patients (41.2% female; mean age 72 years) included in ENCHANTED at sites in England and Wales, which was 19.5% of alteplase-treated AIS patients registered in the SSNAP registry. Trial participants were significantly older, had lower baseline neurological severity, less likely Asian, and had more premorbid symptoms, hypertension and atrial fibrillation. Although ENCHANTED participants had higher rates of symptomatic intracerebral hemorrhage than those in SSNAP, there were no differences in onset-to-treatment time, levels of disability (assessed by the modified Rankin scale) at hospital discharge, and mortality over 90 days between groups. Conclusions: Despite the high level of participation, equipoise over the dose of alteplase among UK clinician investigators favored the inclusion of older, frailer, milder AIS patients in the ENCHANTED trial.es
dc.identifier.citationRobinson TG, Bray BD, Paley L, et al. Applicability of ENCHANTED trial results to current acute ischemic stroke patients eligible for intravenous thrombolysis in England and Wales: Comparison with the Sentinel Stroke National Audit Programme registry. Int J Stroke. 2019;14(7):678-685. doi:10.1177/1747493019841246es
dc.identifier.urihttps://doi.org/10.1177/1747493019841246es
dc.identifier.urihttp://hdl.handle.net/11447/3399
dc.language.isoenes
dc.publisherSage Publishinges
dc.subjectAcute ischemic strokees
dc.subjectAlteplasees
dc.subjectThrombolysis.es
dc.titleApplicability of ENCHANTED trial results to current acute ischemic stroke patients eligible for intravenous thrombolysis in England and Wales: Comparison with the Sentinel Stroke National Audit Programme registryes
dc.typeArticlees

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Applicability of ENCHANTED trial results to current acute ischemic stroke patients eligible for intravenous thrombolysis... - Lavados P.pdf
Size:
3.08 MB
Format:
Adobe Portable Document Format
Description:
Texto completo
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: